Drug name - Vascepa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700537 AMARIN PHARMS Composition for preventing the occurrence of cardiovascular event in multiple risk patient May, 2027

(4 years from now)

US9198892 AMARIN PHARMS Composition and/or method for preventing onset and/or recurrence of cardiovascular events Sep, 2027

(4 years from now)

US8314086 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8293727 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8524698 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8546372 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8415335 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8680144 AMARIN PHARMS Methods of treating mixed dyslipidemia Feb, 2030

(7 years from now)

US8318715 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8518929 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8367652 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8440650 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8357677 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8377920 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8426399 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8399446 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8431560 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8293728 AMARIN PHARMS Methods of treating hypertriglyceridemia Feb, 2030

(7 years from now)

US8298554 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8501225 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8445013 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8617594 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8445003 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8623406 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8617593 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8454994 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8618166 AMARIN PHARMS Methods of treating mixed dyslipidemia Apr, 2030

(7 years from now)

US8642077 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8703185 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8691871 AMARIN PHARMS Methods of treating mixed dyslipidemia Apr, 2030

(7 years from now)

US8709475 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US10010517 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US10265287 AMARIN PHARMS Methods of reducing triglycerides and LDL-C Apr, 2030

(7 years from now)

US8551521 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US8563608 AMARIN PHARMS Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy Apr, 2030

(7 years from now)

US11154526 AMARIN PHARMS Methods of treating mixed dyslipidemia Apr, 2030

(7 years from now)

US10792267 AMARIN PHARMS Methods of treating mixed dyslipidemia Apr, 2030

(7 years from now)

US10842766 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US10881632 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US11103477 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US11213504 AMARIN PHARMS Stable pharmaceutical composition and methods of using same Apr, 2030

(7 years from now)

US10842768 AMARIN PHARMS Compositions and methods for lowering triglycerides Jun, 2030

(7 years from now)

US8410086 AMARIN PHARMS Compositions and methods for lowering triglycerides Jun, 2030

(7 years from now)

US8669245 AMARIN PHARMS Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy Jun, 2030

(7 years from now)

US8455472 AMARIN PHARMS Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy Jun, 2030

(7 years from now)

US8710041 AMARIN PHARMS Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy Jun, 2030

(7 years from now)

US11116742 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US10894028 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10568861 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10668042 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US10576054 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10792270 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10786478 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US11000499 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US9610272 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9623001 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693984 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693985 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693986 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9918954 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10278935 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10278936 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10278937 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10383840 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US9603826 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10555925 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10555924 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

Drugs and Companies using ICOSAPENT ETHYL ingredient

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia; Use of vascepa as an adjunct to statin therapy to reduce the risk of onset and/or recurrence of cardiovascular events in a patient who has escaped the unstable period after cardiovascular angioplasty; Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; use of vascepa to reduce triglycerides in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; method of reducing tg levels in patient on statin therapy suffering from severe hypertriglyceridemia; Method of reducing tg levels in patient on statin therapy suffering from severe hypertriglyceridemia; method of reducing tg levels in patient suffering from severe hypertriglyceridemia; use of vascepa to treat hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; Use of vascepa to treat mixed dyslipidemia in an adult patient with elevated triglyceride (tg) levels (>=150 mg/dl) and on statin therapy; Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; Use of vascepa to treat hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; Use of vascepa to lower triglycerides in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy; Use of vascepa to reduce triglycerides in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on rosuvastatin therapy; Use of vascepa to reduce triglyceride levels in an adult patient having triglyceride levels of at least about 500 mg/dl, on anticoagulant/antiplatelet/thrombolytic therapy, and having atrial fibrillation and/or atrial flutter; Use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction, stroke, both in an adult patient with type 2 diabetes mellitus; Use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with elevated triglycerides and atrial fibrillation; Use of vascepa to reduce triglyceride levels in an adult patient on statin therapy and having atrial fibrillation and triglyceride levels of greater than 500 mg/dl; Use of vascepa as an adjunct to statin therapy to reduce the risk myocardial infarction in an adult patient having atrial fibrillation or atrial flutter and elevated triglyceride levels; Use of vascepa to reduce triglyceride levels in an adult patient on statin therapy and having atrial fibrillation or atrial flutter and triglyceride levels of about 500 mg/dl to about 2,000 mg/dl; Use of vascepa to lower triglycerides and ldl-c in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy; Use of vascepa to lower triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in a patient with prior percutaneous coronary intervention; Use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction in an adult patient with elevated triglyceride levels and established cv disease or diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease; Use of vascepa with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established cv disease, or (2) diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a third and further cardiovascular event in an adult patient with elevated tg levels (>=150 mg/dl) and established cardiovascular disease; use of vascepa as an adjunct to statin therapy to reduce the risk of a second or further cardiovascular (cv) event in an adult patient with elevated tg levels (>= 150 mg/dl) and diabetes mellitus and 2 or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a second and further cardiovascular event in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM CAPSULE;ORAL Prescription
500MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.